Michael Khan
Vorstandsvorsitzender bei Argonaute RNA Ltd.
Profil
Michael Khan is currently the Chief Executive Officer at Argonaute RNA Ltd.
He is also a member of Diabetes UK and HEART UK.
Previously, he was the Executive Director & Chief Medical Officer at Silence Therapeutics Plc from 2013 to 2016.
He also worked as the Head-Molecular Medicine & Associate Professor at the University of Warwick.
Dr. Khan holds a doctorate degree from University College London.
Aktive Positionen von Michael Khan
| Unternehmen | Position | Beginn |
|---|---|---|
| HEART UK | Corporate Officer/Principal | - |
| Diabetes UK | Corporate Officer/Principal | - |
Argonaute RNA Ltd.
 Argonaute RNA Ltd. Miscellaneous Commercial ServicesCommercial Services Argonaute RNA Ltd. develops safe and reliable methods of temporarily silencing target genes in different tissue cells. The company is based in Bristol, UK. Michael Khan has been the CEO of the British company since 2021. | Vorstandsvorsitzender | 01.01.2021 |
Ehemalige bekannte Positionen von Michael Khan
| Unternehmen | Position | Ende |
|---|---|---|
| SILENCE THERAPEUTICS PLC | Technik-/Wissenschafts-/F&E-Leiter | 17.06.2016 |
| University of Warwick | Corporate Officer/Principal | - |
Ausbildung von Michael Khan
| University College London | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SILENCE THERAPEUTICS PLC | Commercial Services |
| Private Unternehmen | 3 |
|---|---|
| Diabetes UK | |
| HEART UK | |
Argonaute RNA Ltd.
Argonaute RNA Ltd. Miscellaneous Commercial ServicesCommercial Services Argonaute RNA Ltd. develops safe and reliable methods of temporarily silencing target genes in different tissue cells. The company is based in Bristol, UK. Michael Khan has been the CEO of the British company since 2021. | Commercial Services |